RiboMed, AIT Partner on Epigenetics-based Lung Cancer Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenetics-based molecular diagnostics company RiboMed Biotechnologies today announced a partnership with the Austrian Institute of Technology to develop and commercialize an assay based on lung cancer DNA methylation biomarkers discovered and validated by researchers at the institute.

The biomarkers allow for the early detection of lung cancer, as well as the subtyping of non-small cell lung cancer into adenocarcinoma or squamous cell carcinoma, which are treated with different therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.